Rigel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Rigel Pharmaceuticals has a total shareholder equity of $-14.6M and total debt of $99.7M, which brings its debt-to-equity ratio to -681.5%. Its total assets and total liabilities are $139.4M and $154.1M respectively. Rigel Pharmaceuticals's EBIT is $9.4M making its interest coverage ratio 1.7. It has cash and short-term investments of $61.1M.
Key information
-681.5%
Debt to equity ratio
US$99.74m
Debt
| Interest coverage ratio | 1.7x |
| Cash | US$61.11m |
| Equity | -US$14.64m |
| Total liabilities | US$154.06m |
| Total assets | US$139.42m |
Recent financial health updates
Recent updates
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Nov 08
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Oct 10Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth
Sep 25There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise
Jul 30Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Jul 24Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?
Oct 25Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib
Oct 10Rigel Pharma adds ~7% to reach over two month high
Aug 18Rigel rises 17% on strong Q2 result
Aug 03Rigel Pharmaceuticals: A Status Check
May 31Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21Rigel Pharmaceuticals: Why The Stock Is On A Run
Mar 21Financial Position Analysis
Short Term Liabilities: RIGL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: RIGL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: RIGL has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: RIGL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: RIGL's debt is not well covered by operating cash flow (10.8%).
Interest Coverage: RIGL's interest payments on its debt are not well covered by EBIT (1.7x coverage).